Converging preclinical, and human epidemiological, neuroimaging, and genetic evidence suggests a central role for dopamine neurotransmission in modulating pain perception and analgesia. Dysregulation in dopamine signaling may modulate the experience of pain both directly, by enhancing or diminishing the propagation of nociceptive signals, and indirectly, by influencing affective and cognitive processes, which affect the expectation, experience, and interpretation of nociceptive signals. Hypersensitivity to pain and high rates of comorbid chronic pain are common in disorders linked with deficits in dopamine system function, including disorders of mood and affect, substance abuse, and Parkinson disease. Hyposensitivity to pain, however, is common in patients with schizophrenia, which has been linked with excessive dopamine neurotransmission. Although patients are typically affected most by the primary symptoms of their disorders, alterations in pain perception may further increase the burden of their illness, compromising their quality of life. The present review focuses on this relationship, and discusses clinical and potential therapeutic implications for both patients with dopamine-related disorders and those with chronic pain syndromes.
Introduction
Individual differences in sensitivity to pain, and the capacity to recruit endogenous antinociceptive systems to counteract noxious stimuli, reflect natural variability in central pain-processing systems. While it is well established that endogenous opioids play a key role in modulating these systems [44, 175] [25] , which enhance DA neurotransmission. Given this link between analgesia and DA signaling, one would expect that hyper-responsivity to pain may occur at unexpectedly high rates in patients with disorders that involve abnormalities in DA functioning, including disorders of mood and affect, schizophrenia, substance abuse, and Parkinson disease [16] . Although these patients are generally affected most by the primary symptoms of their disorders, the impact of dysregulated DA signaling systems on pain perception may further increase the burden of their illness, compromising their quality of life. This review focuses on this relationship, and discusses clinical and therapeutic implications both for patients with DA-related disorders, and those with chronic pain syndromes.
The cerebral dopamine system

The functional neuroanatomy of the dopamine system
Several neuroanatomical pathways, involving the brain regions illustrated in Fig. 1C , support DA signaling across the brain. Neurons that comprise the nigrostriatal DA pathway project from the substantia nigra to dorsal striatal structures, including globus pallidus, putamen, and caudate nucleus. This pathway, which degenerates in patients with Parkinson disease, has a well-established function in sensorimotor coordination and control. The mesocorticolimbic DA pathway is comprised of neurons that project from the ventral tegmental area of the midbrain to subcortical structures, such as the nucleus accumbens, thalamus, hippocampus, and amygdala. Distinct projections from the ventral tegmental area also innervate cortical regions, including ventromedial,
